Eli Lilly (LLY) partners with SanegeneBio in a deal worth up to $1.2B to develop and commercialize RNAi therapeutics for ...

Early results of Eli Lilly’s next generation of weight loss drugs appear to show promise, possibly leading to even faster ...

Experimental pill versions of GLP-1 weight loss drugs by Novo Nordisk and Eli Lilly will receive FDA priority review. Read ...

A new weight-loss drug from Eli Lilly & Co. helped patients shed as much weight as popular shots like Zepbound, giving the company another edge in the fast-growing obesity market.

Eli Lilly expanded its AI drug discovery pact with XtalPi to antibodies. Celltrion in-licensed two innovative autoimmune ...

The drugmaker said it would launch late-stage trials of the drug after participants lost as much as 20% of their body weight.

Eli Lilly said on Thursday it will start late-stage trials of its experimental drug next month after it helped patients lose as much as 20.1% of their weight in a mid-stage study, giving the company ...

Eli Lilly is doubling down on its partnership with Chinese tech outfit XtalPi, striking a new antibody development pact that ...

· Eli Lilly and Company announced it is building the most powerful supercomputer owned and operated by a pharmaceutical ...

This next-gen weight-loss drug offers a new hope — and a bonus Ozempic and Wegovy don’t have - The once-weekly shot may be a ...

The Alliance for Building Better Medicine (ABBM) and the Virginia Innovation Partnership Corporation (VIPC) celebrated Governor Glenn Youngkin's announcement of $120 million in private industry ...